• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960


August 30, 2021

First Quarter 2022 Financial Results

Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific’s network of clinics, including a Ketamine trial for Bipolar Depression, a Ketamine trial to rapidly reduce suicidality, and the first multiple-dose psilocybin trial to combat treatment-resistant depression TORONTO, ONTARIO Aug. 30, 2021 – Braxia Scientific Corp. (“Braxia Scientific,” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be...